Board Change • Jul 01
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. 2 highly experienced directors. Independent Outside Director Nanako Tamiya was the last director to join the board, commencing their role in 2026. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Jun 12
JMDC Inc. to Report Q1, 2027 Results on Aug 05, 2026 JMDC Inc. announced that they will report Q1, 2027 results on Aug 05, 2026 Announcement • Dec 12
JMDC Inc. to Report Q3, 2026 Results on Feb 05, 2026 JMDC Inc. announced that they will report Q3, 2026 results on Feb 05, 2026 Announcement • Sep 01
JMDC Inc. to Report Q2, 2026 Results on Nov 06, 2025 JMDC Inc. announced that they will report Q2, 2026 results on Nov 06, 2025 Announcement • May 18
JMDC Inc. to Report Q1, 2026 Results on Aug 06, 2025 JMDC Inc. announced that they will report Q1, 2026 results on Aug 06, 2025 Announcement • May 07
JMDC Inc., Annual General Meeting, Jun 25, 2025 JMDC Inc., Annual General Meeting, Jun 25, 2025. Announcement • Mar 13
JMDC Inc. to Report Fiscal Year 2025 Results on May 07, 2025 JMDC Inc. announced that they will report fiscal year 2025 results on May 07, 2025 Announcement • Feb 20
Kakehashi Co., Ltd. agreed to acquire Noah Medical System K.K. from JMDC Inc. (TSE:4483) for ¥3.0 billion. Kakehashi Co., Ltd. agreed to acquire Noah Medical System K.K. from JMDC Inc. (TSE:4483) for ¥3.0 billion on February 20, 2025. A cash consideration of ¥3 billion will be paid by Kakehashi Co., Ltd. As part of consideration, ¥3 billion is paid towards common equity of Noah Medical System K.K.
For the period ending March 31, 2024, Noah Medical System K.K. reported total revenue of ¥1.22 billion, EBIT of ¥134 million and net income of ¥97 million. As of March 31, 2024, Noah Medical System K.K. reported total assets of ¥921 million and total common equity of ¥669 million.
The expected completion of the transaction is February 21, 2025. Announcement • Dec 11
JMDC Inc. to Report Q3, 2025 Results on Feb 05, 2025 JMDC Inc. announced that they will report Q3, 2025 results on Feb 05, 2025 Reported Earnings • Nov 07
Second quarter 2025 earnings released: EPS: JP¥22.37 (vs JP¥9.82 in 2Q 2024) Second quarter 2025 results: EPS: JP¥22.37 (up from JP¥9.82 in 2Q 2024). Revenue: JP¥10.8b (up 53% from 2Q 2024). Net income: JP¥1.46b (up 135% from 2Q 2024). Profit margin: 14% (up from 8.8% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Healthcare Services industry in Europe. Announcement • Sep 06
JMDC Inc. to Report Q2, 2025 Results on Nov 05, 2024 JMDC Inc. announced that they will report Q2, 2025 results on Nov 05, 2024 Reported Earnings • Aug 05
First quarter 2025 earnings released: EPS: JP¥11.13 (vs JP¥32.41 in 1Q 2024) First quarter 2025 results: EPS: JP¥11.13 (down from JP¥32.41 in 1Q 2024). Revenue: JP¥8.42b (up 26% from 1Q 2024). Net income: JP¥727.0m (down 64% from 1Q 2024). Profit margin: 8.6% (down from 31% in 1Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in Europe. Valuation Update With 7 Day Price Move • Jul 13
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to €20.20, the stock trades at a forward P/E ratio of 37x. Average forward P/E is 18x in the Healthcare Services industry in Europe. Total loss to shareholders of 42% over the past year. Announcement • Jun 21
JMDC Inc. to Report Q1, 2025 Results on Aug 02, 2024 JMDC Inc. announced that they will report Q1, 2025 results on Aug 02, 2024 New Risk • Jun 12
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Shareholders have been diluted in the past year (3.8% increase in shares outstanding). Valuation Update With 7 Day Price Move • Jun 05
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to €17.40, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 19x in the Healthcare Services industry in Europe. Total loss to shareholders of 55% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €12.54 per share. Buy Or Sell Opportunity • Jun 01
Now 26% overvalued Over the last 90 days, the stock has fallen 32% to €15.70. The fair value is estimated to be €12.50, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has grown by 20%. For the next 3 years, revenue is forecast to grow by 16% per annum. Earnings are also forecast to grow by 20% per annum over the same time period. Reported Earnings • May 08
Full year 2024 earnings released: EPS: JP¥71.76 (vs JP¥71.16 in FY 2023) Full year 2024 results: EPS: JP¥71.76 (up from JP¥71.16 in FY 2023). Revenue: JP¥32.4b (up 16% from FY 2023). Net income: JP¥4.61b (up 8.0% from FY 2023). Profit margin: 14% (down from 15% in FY 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Healthcare Services industry in Europe. Announcement • Mar 24
JMDC Inc. to Report Fiscal Year 2024 Results on May 07, 2024 JMDC Inc. announced that they will report fiscal year 2024 results on May 07, 2024 Upcoming Dividend • Mar 21
Upcoming dividend of JP¥12.00 per share Eligible shareholders must have bought the stock before 28 March 2024. Payment date: 07 June 2024. Payout ratio is a comfortable 14% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of German dividend payers (4.9%). Lower than average of industry peers (1.5%). Reported Earnings • Feb 04
Third quarter 2024 earnings released: EPS: JP¥20.13 (vs JP¥19.27 in 3Q 2023) Third quarter 2024 results: EPS: JP¥20.13 (up from JP¥19.27 in 3Q 2023). Revenue: JP¥8.54b (up 14% from 3Q 2023). Net income: JP¥1.32b (up 8.7% from 3Q 2023). Profit margin: 15% (in line with 3Q 2023). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 8.7% growth forecast for the Healthcare Services industry in Europe. Announcement • Dec 24
JMDC Inc. to Report Q3, 2024 Results on Feb 02, 2024 JMDC Inc. announced that they will report Q3, 2024 results on Feb 02, 2024 Reported Earnings • Nov 04
Second quarter 2024 earnings released: EPS: JP¥9.83 (vs JP¥11.75 in 2Q 2023) Second quarter 2024 results: EPS: JP¥9.83 (down from JP¥11.75 in 2Q 2023). Revenue: JP¥7.05b (up 12% from 2Q 2023). Net income: JP¥622.0m (down 8.3% from 2Q 2023). Profit margin: 8.8% (down from 11% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 7.5% growth forecast for the Healthcare Services industry in Europe. Valuation Update With 7 Day Price Move • Oct 25
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to €28.20, the stock trades at a forward P/E ratio of 45x. Average forward P/E is 17x in the Healthcare Services industry in Europe. Total loss to shareholders of 18% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €21.02 per share. Announcement • Oct 12
OMRON Corporation (TSE:6645) completed the acquisition of 23.09% stake in JMDC Inc. (TSE:4483) for approximately ¥85.5 billion. OMRON Corporation (TSE:6645) made an offer to acquire 18.52% stake in JMDC Inc. (TSE:4483) for approximately ¥68.6 billion on September 8, 2023. The tender offer price is ¥5,700 per share of common stock. OMRON Corporation is the largest shareholder and a major shareholder holding 20,459,000 shares (ownership ratio: 31.49%) of the JMDC Inc's shares, which make the Company an equity-method affiliate of the Offeror. The Tender Offeror aims to make the JMDC Inc. a consolidated subsidiary through the Tender Offer, set the minimum number of shares sought for purchase as 12,036,700 shares.
OMRON Corporation (TSE:6645) completed the acquisition of 23.09% stake in JMDC Inc. (TSE:4483) for approximately ¥85.5 billion on October 10, 2023. On completion, OMRON Corporation acquired 15,000,000 shares and post tender offer number of shares owned after change will stand at 35,459,000 shares representing 54.57% interest in JMDC Inc. held by OMRON Corporation. As a result of the Tender Offer, the JMDC Inc is scheduled to become a consolidated subsidiary of the OMRON Corporation. New Risk • Oct 10
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 4.1% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.2% average weekly change). Shareholders have been diluted in the past year (4.1% increase in shares outstanding). Announcement • Sep 24
JMDC Inc. to Report Q2, 2024 Results on Nov 02, 2023 JMDC Inc. announced that they will report Q2, 2024 results on Nov 02, 2023 Valuation Update With 7 Day Price Move • Sep 11
Investor sentiment improves as stock rises 24% After last week's 24% share price gain to €33.40, the stock trades at a forward P/E ratio of 51x. Average forward P/E is 18x in the Healthcare Services industry in Europe. Simply Wall St's valuation model estimates the intrinsic value at €21.64 per share. Valuation Update With 7 Day Price Move • Aug 17
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to €26.00, the stock trades at a forward P/E ratio of 42x. Average forward P/E is 23x in the Healthcare Services industry in Europe. Simply Wall St's valuation model estimates the intrinsic value at €23.17 per share. Reported Earnings • Aug 10
First quarter 2024 earnings released: EPS: JP¥32.41 (vs JP¥13.53 in 1Q 2023) First quarter 2024 results: EPS: JP¥32.41 (up from JP¥13.53 in 1Q 2023). Revenue: JP¥6.70b (up 16% from 1Q 2023). Net income: JP¥2.04b (up 167% from 1Q 2023). Profit margin: 31% (up from 13% in 1Q 2023). The increase in margin was primarily driven by higher revenue. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 7.7% growth forecast for the Healthcare Services industry in Europe. Board Change • Jul 26
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 8 non-independent directors. President, CEO & Representative Director Ryo Noguchi was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. 
